UK Regulators Mandate New Warnings for Antidepressants Over Persistent Sexual Dysfunction Risks

The Medicines and Healthcare products Regulatory Agency (MHRA) has announced a significant update to patient information leaflets for antidepressants. Following an extensive review by the Commission on Human Medicines, regulators will now mandate boxed warnings regarding the risk of suicidal thoughts and, crucially, the potential for long-lasting sexual side effects. This move marks the first time health authorities have explicitly acknowledged that sexual dysfunction linked to certain antidepressants can persist long after a patient has ceased treatment.

Dr. Alison Cave, chief safety officer at the MHRA, emphasized that the initiative aims to provide patients with clear, accessible information to facilitate informed decision-making. While maintaining that antidepressants remain effective for treating depression and anxiety, the agency stressed that the benefits must be weighed against these documented risks. The updated guidance specifically highlights symptoms such as genital numbness, erectile dysfunction, loss of libido, and difficulty reaching orgasm, collectively referred to as Post-SSRI Sexual Dysfunction (PSSD).

Approximately one in seven adults in the UK currently takes antidepressants, with NHS data indicating that half of these patients have been on the medication for over two years. The updated warnings will specifically apply to drugs such as duloxetine, fluvoxamine, and fluoxetine, which have been associated with these persistent symptoms. Other medications, including mirtazapine, vortioxetine, and agomelatine, were not included in this specific update, though the MHRA continues to monitor all psychiatric drug safety profiles.

Patients currently prescribed these medications will begin receiving the updated information leaflets in 2027. Health officials have issued a stern advisory against stopping medication suddenly, urging patients to consult with healthcare professionals before making any changes to their treatment plans. This regulatory shift reflects a growing global recognition of PSSD, aiming to bridge the gap between clinical efficacy and patient-reported long-term health outcomes.